HIL2-RO

Applied Filters:

Keyword:'HIL2-RO'

Showing 1-6 of 6 results for "HIL2-RO" within Papers

Biallelic mutations in calcium release activated channel regulator 2A (CRACR2A) cause a primary immunodeficiency disorder.

Beibei Wu et al.

eLife, 10 (2021-12-16)

CRAC channel regulator 2 A (CRACR2A) is a large Rab GTPase that is expressed abundantly in T cells and acts as a signal transmitter between T cell receptor stimulation and activation of the Ca2+-NFAT and JNK-AP1 pathways. CRACR2A has been

Specific dietary oligosaccharides increase Th1 responses in a mouse respiratory syncytial virus infection model.

Marcel A Schijf et al.

Journal of virology, 86(21), 11472-11482 (2012-08-17)

Breast feeding reduces the risk of developing severe respiratory syncytial virus (RSV) infections in infants. In addition to maternal antibodies, other immune-modulating factors in human milk contribute to this protection. Specific dietary prebiotic oligosaccharides, similar to oligosaccharides present in human

Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription.

Koen Bartholomeeusen et al.

The Journal of biological chemistry, 288(20), 14400-14407 (2013-03-30)

Numerous studies have looked at the effects of histone deacetylase inhibitors (HDACis) on HIV reactivation in established transformed cell lines and primary CD4(+) T cells. However, their findings remain confusing, and differences between effects of class I- and class II-specific

In CD28-costimulated human naïve CD4+ T cells, I-κB kinase controls the expression of cell cycle regulatory proteins via interleukin-2-independent mechanisms.

Elisa Lupino et al.

Immunology, 131(2), 231-241 (2010-05-15)

Stimulation of naïve CD4(+) T cells through engagement of the T-cell receptor (TCR) and the CD28 co-receptor initiates cell proliferation which critically depends on interleukin (IL)-2 secretion and subsequent autocrine signalling via the IL-2 receptor. However, several studies indicate that

Low-dose interleukin-2 therapy: a driver of an imbalance between immune tolerance and autoimmunity.

Agata Kosmaczewska

International journal of molecular sciences, 15(10), 18574-18592 (2014-10-17)

For many years, the role of interleukin-2 (IL-2) in autoimmune responses was established as a cytokine possessing strong pro-inflammatory activity. Studies of the past few years have changed our knowledge on IL-2 in autoimmune chronic inflammation, suggesting its protective role

Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation.

Christoph Schliemann et al.

Cancer immunology research, 3(5), 547-556 (2015-02-13)

The antibody-based delivery of IL2 to extracellular targets expressed in the easily accessible tumor-associated vasculature has shown potent antileukemic activity in xenograft and immunocompetent murine models of acute myelogenous leukemia (AML), especially in combination with cytarabine. Here, we report our

Page 1 of 1